Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha
- PMID: 11743648
Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha
Abstract
Valproic acid (VPA) has been shown to induce growth-arrest and differentiation of human neuroectodermal tumors similarly to several other fatty acids. In the present study, we show that continuous VPA treatment together with Interferon-alpha (INF-alpha) synergistically inhibited cell growth of a well-established model of neuroblastoma (NB) differentiation using the human N-myc amplified cell line BE(2)-C. Suppression of tumor growth was accompanied by morphological features of neuronal differentiation and inhibition of histone deacetylase activity. Furthermore, induction of differentiation was concomitant with altered expression of genes related to malignant phenotype such as down-regulation of N-myc, induction of bcl-2 and neural cell adhesion molecule. Production of inhibitors of angiogenesis like thrombospondin-1 and activin A was up-regulated in differentiated NB cells. Treatment with VPA alone decreased the ability of BE(2)-C cells to adhere to and penetrate human endothelium. All these effects of VPA were significantly enhanced when combined with INF-alpha which on its own had little or no effect. These results suggest that combination of VPA and INF-alpha may provide a novel therapeutic strategy for NB due to enhanced inhibition of tumor cell growth, induction of tumor differentiation and suppression of malignant biology by reduced angiogenic and decreased metastatic potentials.
Similar articles
-
p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.Oncol Rep. 2005 Jun;13(6):1139-44. Oncol Rep. 2005. PMID: 15870934
-
Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo.Int J Oncol. 2004 Dec;25(6):1795-9. Int J Oncol. 2004. PMID: 15547719
-
HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness.Cancer Res. 1999 May 15;59(10):2484-92. Cancer Res. 1999. PMID: 10344762
-
Valproic acid for the treatment of pediatric malignant glioma.Klin Padiatr. 1999 Jul-Aug;211(4):323-8. doi: 10.1055/s-2008-1043809. Klin Padiatr. 1999. PMID: 10472571 Review.
-
Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.Med Res Rev. 2005 Jul;25(4):383-97. doi: 10.1002/med.20027. Med Res Rev. 2005. PMID: 15637697 Review.
Cited by
-
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9751-6. doi: 10.1073/pnas.0710413105. Epub 2008 Jul 7. Proc Natl Acad Sci U S A. 2008. PMID: 18607002 Free PMC article.
-
Histone Deacetylase Inhibitors as Anticancer Drugs.Int J Mol Sci. 2017 Jul 1;18(7):1414. doi: 10.3390/ijms18071414. Int J Mol Sci. 2017. PMID: 28671573 Free PMC article. Review.
-
HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases.Transl Oncol. 2022 Feb;16:101312. doi: 10.1016/j.tranon.2021.101312. Epub 2021 Dec 16. Transl Oncol. 2022. PMID: 34922087 Free PMC article. Review.
-
Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.Pharmaceuticals (Basel). 2010 Apr 23;3(4):1241-1278. doi: 10.3390/ph3041241. Pharmaceuticals (Basel). 2010. PMID: 27713299 Free PMC article. Review.
-
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.J Cell Mol Med. 2009 Aug;13(8B):2342-2352. doi: 10.1111/j.1582-4934.2008.00603.x. J Cell Mol Med. 2009. PMID: 19067765 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical